Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Investigate common budgeting blockers that prevent savings and identify actionable changes. This intro guides you toward steady, growing savings.
27,247 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
The housing story of 2026 isn’t about a vanished dream. It’s about where the American Dream still thrives—where build...
Choosing the right pharmaceutical ETF can shape your portfolio’s risk and income. This guide pits IHE against PJP, br...
Investors are buzzing about a hypothetical $165 billion payout for Elon Musk tied to SpaceX milestones. Traders say t...
Is a $5 trillion Apple valuation possible by the end of 2026? This guide weighs the growth engines, risks, and action...
A veteran analyst warns that today may be one of the most dangerous eras for passive investing. With stocks near all-...
A single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
A tech-focused investor known for hunting winners, billionaire Philippe Laffont just rotated from a high-profile AI p...
A high-profile investor sends a pointed message about Whirlpool’s strategy. This article explains what the billionair...
February was brutal for some software names. This piece breaks down why monday.com stock lost february, what that sig...
As higher interest rates bite into fixed retiree incomes, Suze Orman argues that paying only the minimum on credit ca...
Forbes' 2026 Billionaires List puts Binance founder CZ ahead of Bill Gates, prompting debate over crypto wealth and h...